NDC 63037-101-10
This exact product or package identity exists in FDA auxiliary data but is not present in the current primary NDC product table. The package identity is preserved; status rows are reported source observations, not medical conclusions.
- Requested NDC
- 63037-101-10
- Product root
- 63037-101
- Identity scope
- Package
- Primary current NDC product row
- Not present
NDC auxiliary status#
These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| compounder | package | 63037-101 | 63037-101-10 | COMPOUNDER | Outsourcing facility compounded drug report | 2026-1 | 2026-09-18 |
| compounder | package | 63037-101 | 63037-101-10 | COMPOUNDER | Outsourcing facility compounded drug report | 2026-1 | 2026-10-06 |
Compounder NDC reports#
| Establishment | FEI | Product NDC | Package NDC | Product | Active ingredients | Reporting period | Normalization |
|---|---|---|---|---|---|---|---|
| Hikma Injectables USA Inc. | 63037-101 | 63037-101-10 | Fentanyl Citrate in 0.9% Sodium Chloride Injection | 2500 ug/250 mL | 2026-1 | valid | |
| Hikma Pharmaceuticals USA Inc. | 946499746 | 63037-101 | 63037-101-10 | Fentanyl Citrate | 2500 ug/250 mL | 2026-1 | valid |
| Hikma Injectables USA Inc. | 63037-101 | 63037-101-05 | Fentanyl Citrate in 0.9% Sodium Chloride Injection | 2500 ug/250 mL | 2025-2 | valid | |
| Hikma Pharmaceuticals USA Inc. | 946499746 | 63037-101 | 63037-101-05 | Fentanyl Citrate | 2500 ug/250 mL | 2025-2 | valid |
| Hikma Injectables USA Inc. | 63037-101 | 63037-101-05 | Fentanyl Citrate in 0.9% Sodium Chloride Injection | 2500 ug/250 mL | 2025-1 | valid | |
| Hikma Pharmaceuticals USA Inc. | 946499746 | 63037-101 | 63037-101-05 | Fentanyl Citrate | 2500 ug/250 mL | 2025-1 | valid |
| Hikma Injectables USA Inc. | 63037-101 | 63037-101-05 | Fentanyl Citrate in 0.9% Sodium Chloride Injection | 2500 ug/250 mL | 2024-2 | valid | |
| Hikma Pharmaceuticals USA Inc. | 946499746 | 63037-101 | 63037-101-05 | Fentanyl Citrate | 2500 ug/250 mL | 2024-2 | valid |
| Hikma Pharmaceuticals USA Inc. | 946499746 | 63037-101 | 63037-101-05 | Fentanyl Citrate | 2500 ug/250 mL | 2024-1 | valid |
| Hikma Pharmaceuticals USA Inc. | 946499746 | 63037-101 | 63037-101-05 | Fentanyl Citrate | 2500 ug/250 mL | 2023-2 | valid |
| Hikma Pharmaceuticals USA Inc. | 946499746 | 63037-101 | 63037-101-05 | Fentanyl Citrate | 2500 ug/250 mL | 2023-1 | valid |
| Hikma Pharmaceuticals USA Inc. | 946499746 | 63037-101 | 63037-101-05 | Fentanyl Citrate | 2500 ug/250 mL | 2022-2 | valid |
| Hikma Pharmaceuticals USA Inc. | 946499746 | 63037-101 | 63037-101-05 | Fentanyl Citrate | 2500 ug/250 mL | 2022-1 | valid |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.